Format

Send to

Choose Destination
See comment in PubMed Commons below
PLoS One. 2011;6(12):e28025. doi: 10.1371/journal.pone.0028025. Epub 2011 Dec 21.

Systematic drug repositioning based on clinical side-effects.

Author information

1
Computational Biology, Quantitative Sciences, Medicines Discovery and Development, GlaxoSmithKline, Philadelphia, Pennsylvania, United States of America. Lun.Yang@gmail.com

Abstract

Drug repositioning helps fully explore indications for marketed drugs and clinical candidates. Here we show that the clinical side-effects (SEs) provide a human phenotypic profile for the drug, and this profile can suggest additional disease indications. We extracted 3,175 SE-disease relationships by combining the SE-drug relationships from drug labels and the drug-disease relationships from PharmGKB. Many relationships provide explicit repositioning hypotheses, such as drugs causing hypoglycemia are potential candidates for diabetes. We built Naïve Bayes models to predict indications for 145 diseases using the SEs as features. The AUC was above 0.8 in 92% of these models. The method was extended to predict indications for clinical compounds, 36% of the models achieved AUC above 0.7. This suggests that closer attention should be paid to the SEs observed in trials not just to evaluate the harmful effects, but also to rationally explore the repositioning potential based on this "clinical phenotypic assay".

PMID:
22205936
PMCID:
PMC3244383
DOI:
10.1371/journal.pone.0028025
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Support Center